On March 29, 2023, the Latvian Institute of Organic Synthesis (LIOS) celebrated the opening of its new Biotechnology facility. The two-story laboratory spaces are equipped with the latest research equipment for molecular and structural biology research, which will enhance LIOS’s capabilities and potential for discovering new drugs.
The two-story Biotechnology building, totaling 550 m2, houses laboratories where LIOS scientists can conduct cutting-edge research in molecular and structural biology and develop biotechnological processes at the laboratory level. Here, it will be possible to obtain biologically relevant proteins necessary for rational drug design, and protein biomaterials for tissue engineering, as well as to develop biocatalytic processes and carry out the early phases of biopharmaceutical development.
With this, the LIOS takes another step forward in improving its drug discovery platform, ensuring a complete early drug discovery and research cycle, from the design of active molecules to manufacturing technology development as well as a wide range of pre-clinical tests.
Before the opening ceremony, there was an opportunity to attend an academic lecture by Professor Virginijus Šikšnys (Vilnius University) on the development of biotechnology in Lithuania. In 2021, the biotechnology industry accounted for 2.5% of Lithuania's GDP, and by 2030, the country hopes to increase this share to 5% of GDP.